文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

静脉氨基酸补充对ICU患者死亡率的影响可能取决于肾功能:多中心随机试验的事后亚组分析

The Effect of IV Amino Acid Supplementation on Mortality in ICU Patients May Be Dependent on Kidney Function: Post Hoc Subgroup Analyses of a Multicenter Randomized Trial.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论事后亚组分析提示,肾功能正常的ICU患者接受静脉氨基酸补充(总蛋白达2.0 g/kg/d)可能降低90天死亡率并改善eGFR,但作者强烈建议在低偏倚风险试验中确认前不推荐常规使用。

该研究为多中心2期随机临床试验的事后、假设生成性亚组分析,纳入澳大利亚和新西兰16家医院ICU的474例成人危重患者,随机分为标准营养护理组(235例)和静脉氨基酸补充组(239例,每日补充最多100 g静脉氨基酸以达到总蛋白摄入2.0 g/kg/d)。主要终点为90天死亡率。基线肾功能与研究干预存在显著交互作用(交互作用P=0.026)。在随机化时肾功能正常的亚组中,氨基酸补充组90天死亡风险较低(协变量校正风险差-7.9%,95%CI -15.1至-0.7,P=0.034),且eGFR显著升高(重复测量治疗×时间交互作用P=0.009);在基线肾功能障碍和/或急性肾损伤进展风险亚组中,未发现干预对死亡率有显著影响(协变量校正风险差-0.6%,95%CI -16.2至15.2,P=0.95)。作者强烈建议在推荐该治疗用于常规护理前,需在低偏倚风险试验中确认这些结果。

要点

  • 在基线肾功能正常的ICU患者中,静脉氨基酸补充(总蛋白2.0 g/kg/d)组90天死亡风险较标准护理组降低,协变量校正风险差-7.9%(95%CI -15.1至-0.7,P=0.034)。
  • 同一亚组中,氨基酸补充显著改善eGFR(重复测量治疗×时间交互作用P=0.009)。
  • 在基线肾功能障碍和/或急性肾损伤进展风险亚组中,干预对死亡率无显著影响(协变量校正风险差-0.6%,95%CI -16.2至15.2,P=0.95)。
  • 基线肾功能与氨基酸补充对死亡率存在显著交互作用(交互作用P=0.026)。
  • 作者强烈建议在低偏倚风险试验中确认这些结果前,不推荐将该治疗用于常规护理。

适用人群与场景

  • 澳大利亚和新西兰16家医院ICU的成人危重患者,预期在研究ICU停留超过2天。

处置流程与药物剂量

  • 静脉氨基酸补充组:每日补充最多100 g静脉氨基酸,以达到总蛋白摄入2.0 g/kg/d;对照组接受标准营养护理。

研究设计与关键结果

  • 研究类型:多中心、2期随机临床试验的事后、假设生成性亚组分析;共随机474例,标准护理组235例,静脉氨基酸补充组239例;所有分析按意向性治疗进行并维持分组。
  • 主要终点90天死亡率:基线肾功能正常亚组中,氨基酸补充组协变量校正风险差-7.9%(95%CI -15.1至-0.7,P=0.034);基线肾功能障碍和/或急性肾损伤进展风险亚组中,协变量校正风险差-0.6%(95%CI -16.2至15.2,P=0.95)。
  • 基线肾功能与氨基酸补充对死亡率存在显著交互作用(交互作用P=0.026)。
  • 基线肾功能正常亚组中,氨基酸补充显著增加eGFR(重复测量治疗×时间交互作用P=0.009)。

证据类型、等级与局限

  • 证据类型:多中心、2期随机临床试验的事后、假设生成性亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者强烈建议在低偏倚风险试验中确认这些结果前,不推荐将该治疗用于常规护理。
  • 事后亚组分析提示,肾功能正常的ICU患者接受静脉氨基酸补充(总蛋白2.0 g/kg/d)可能降低90天死亡率并改善eGFR;肾功能障碍和/或急性肾损伤进展风险患者未观察到死亡率获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: We investigated whether preexisting kidney function determines if ICU patients may benefit from increased (2.0 g/kg/d) protein intake.

DESIGN: Post hoc, hypothesis-generating, subgroup analysis of a multicenter, phase 2, randomized clinical trial. All analyses were conducted by intention to treat and maintained group allocation. Ninety-day mortality was the primary outcome.

SETTING: ICUs of 16 hospitals throughout Australia and New Zealand.

PATIENTS: Adult critically ill patients expected to remain in the study ICU for longer than 2 days.

INTERVENTIONS: Random allocation to receive a daily supplement of up to 100 g of IV amino acids to achieve a total protein intake of 2.0 g/kg/d or standard nutrition care.

MEASUREMENTS AND MAIN RESULTS: A total of 474 patients were randomized: 235 to standard care and 239 to IV amino acid supplementation. There was a statistically significant interaction between baseline kidney function and supplementation with study amino acids (p value for interaction = 0.026). Within the subgroup of patients with normal kidney function at randomization, patients who were allocated to receive the study amino acid supplement were less likely to die before study day 90 (covariate-adjusted risk difference, -7.9%; 95% CI, -15.1 to -0.7; p = 0.034). Furthermore, amino acid supplementation significantly increased estimated glomerular filtration rate in these patients (repeated-measures treatment × time interaction p = 0.009). Within the subgroup of patients with baseline kidney dysfunction and/or risk of progression of acute kidney injury, a significant effect of the study intervention on mortality was not found (covariate-adjusted risk difference, -0.6%; 95% CI, -16.2 to 15.2; p = 0.95).

CONCLUSIONS: In this post hoc, hypothesis-generating, subgroup analysis, we observed reduced mortality and improved estimated glomerular filtration rate in ICU patients with normal kidney function who were randomly allocated to receive increased protein intake (up to 2.0 g/kg/d). We strongly recommend confirmation of these results in trials with low risk of bias before this treatment is recommended for routine care.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Zhu R, Allingstrup MJ, Perner A, et al. The Effect of IV Amino Acid Supplementation on Mortality in ICU Patients May Be Dependent on Kidney Function: Post Hoc Subgroup Analyses of a Multicenter Randomized Trial. Crit Care Med. 2018. PMID: 29771700. doi:10.1097/CCM.0000000000003221

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。